Siddiqi, Shan H. http://orcid.org/0000-0002-0967-9289
Kletenik, Isaiah http://orcid.org/0000-0001-7706-967X
Anderson, Mark C.
Cavallari, Michele
Chitnis, Tanuja
Glanz, Bonnie I. http://orcid.org/0000-0002-4344-3456
Khalil, Samar
Palotai, Miklos
Bakshi, Rohit http://orcid.org/0000-0001-8601-5534
Guttmann, Charles R. G.
Fox, Michael D. http://orcid.org/0000-0001-8848-6399
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K23MH129829)
Article History
Received: 19 May 2022
Accepted: 29 November 2022
First Online: 19 January 2023
Competing interests
: S.H.S. and M.D.F. are scientific consultants for Magnus Medical. S.H.S. is a clinical consultant for Acacia Mental Health, Kaizen Brain Center and Boston Precision Neurotherapeutics. S.H.S. and M.D.F. have jointly received investigator-initiated research funding from Neuronetics. S.H.S. has served as a speaker for Brainsway and PsychU.org (unbranded, sponsored by Otsuka). S.H.S. and M.D.F. independently own intellectual property involving the use of functional connectivity to target TMS. R.B. has received consulting fees from Bristol Myers Squibb and EMD Serono and research support from Bristol Myers Squibb, EMD Serono and Novartis. C.R.G.G. has received research funding from Sanofi, the National Multiple Sclerosis Society, the International Progressive Multiple Sclerosis Alliance, the US Office for Naval Research, NIH, the Focused Ultrasound Foundation, Bristol Myers Squibb/Celgene as well as travel support from Roche Pharmaceuticals, and owns stock in Roche, Novartis, GSK, Alnylam, Protalix Biotherapeutics, Arrowhead Pharmaceuticals, Cocrystal Pharma and Sangamo Therapeutics. None of these entities was involved in the present work. The remaining authors have no conflicts of interest to declare.